Advertisement
HBIO vs NPCE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Buy and NPCE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HBIO’s FA Score shows that 1 FA rating(s) are green whileNPCE’s FA Score has 0 green FA rating(s).
- HBIO’s FA Score: 1 green, 4 red.
- NPCE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HBIO’s TA Score shows that 1 TA indicator(s) are bullish while NPCE’s TA Score has 5 bullish TA indicator(s).
- HBIO’s TA Score: 1 bullish, 7 bearish.
- NPCE’s TA Score: 5 bullish, 3 bearish.
Price Growth
HBIO (@Pharmaceuticals: Other) experienced а -5.93% price change this week, while NPCE (@Medical/Nursing Services) price change was +2.62% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.23%. For the same industry, the average monthly price growth was -3.27%, and the average quarterly price growth was +8.57%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was +3.18%, and the average quarterly price growth was +9.30%.
Reported Earning Dates
HBIO is expected to report earnings on Nov 06, 2025.
NPCE is expected to report earnings on Nov 11, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-1.23% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| HBIO | NPCE | HBIO / NPCE | |
| Capitalization | 19.8M | 337M | 6% |
| EBITDA | -46.8M | -15.52M | 302% |
| Gain YTD | -78.962 | -8.847 | 893% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 88.8M | 88.6M | 100% |
| Total Cash | 7.44M | 62.1M | 12% |
| Total Debt | 43.3M | 71.5M | 61% |
HBIO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 91 | |
P/E GROWTH RATING 1..100 | 2 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| HBIO | NPCE | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 81% | N/A |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 83% |
| Advances ODDS (%) | N/A | 4 days ago 85% |
| Declines ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 68% | N/A |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Advertisement
HBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.
| Ticker / NAME | Correlation To HBIO | 1D Price Change % | ||
|---|---|---|---|---|
| HBIO | 100% | +1.07% | ||
| IRMD - HBIO | 51% Loosely correlated | +2.51% | ||
| SGHT - HBIO | 39% Loosely correlated | +1.46% | ||
| A - HBIO | 38% Loosely correlated | +1.23% | ||
| TMO - HBIO | 35% Loosely correlated | +1.09% | ||
| MTD - HBIO | 35% Loosely correlated | -0.42% | ||
More | ||||
NPCE and
Correlation & Price change
A.I.dvisor indicates that over the last year, NPCE has been loosely correlated with STVN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NPCE jumps, then STVN could also see price increases.
| Ticker / NAME | Correlation To NPCE | 1D Price Change % | ||
|---|---|---|---|---|
| NPCE | 100% | +1.90% | ||
| STVN - NPCE | 37% Loosely correlated | +2.23% | ||
| HBIO - NPCE | 32% Poorly correlated | +1.07% | ||
| SMTI - NPCE | 30% Poorly correlated | +1.95% | ||
| NTRA - NPCE | 30% Poorly correlated | -0.42% | ||
| ATRC - NPCE | 29% Poorly correlated | +0.49% | ||
More | ||||